Chimeric antigen receptor T-cell therapy has been really instrumental in how we treat patients with myeloma. It has really changed the face of how we treat this disease, so since 2021, we've had two ...

Although the treatment of myeloma has changed dramatically after the readout of many recent trials, key unanswered questions ...

This review summarizes the mechanisms of action and clinical activity of IMiDs in MM. Multiple myeloma (MM) is a malignant plasma cell disorder accounting for approximately 10% of all hematologic ...

In summary, MYC activation may be a common transforming event in myeloma. This activation may be mediated by multiple mechanisms, and tumors with MYC activation have a more aggressive course ...

1 Multiple myeloma originates in blood plasma cells ... sometimes without warning, and the mechanisms that render the disease incurable are not well understood. Many patients therefore require ...

Daratumumab plus VRd significantly improves survival in newly diagnosed multiple myeloma, supporting its role as a new ...

The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...

A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal ...

When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response ...

Hong Kong Department of Health accepts IASO Bio’s NDA for equecabtagene autoleucel to treat r/r multiple myeloma: Shanghai, Nanjing Monday, February 17, 2025, 17:00 Hrs [IST] IA ...

Antengene’s Xpovio approved for reimbursement in Taiwan to treat adult patients with relapsed/refractory multiple myeloma: Shanghai Friday, February 14, 2025, 16:00 Hrs [IST] An ...